Skip to main content
SpringerLink
Log in

Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas

A Southwest Oncology Group study

  • Phase II Clinical Trials
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Piroxantrone is an anthrapyrazole compound undergoing phase II testing in a variety of diseases. The anthrapyrazoles are a series of compounds synthesized with the intent of maintaining the broad antitumor activity of anthracyclines, but with lessened cardiac toxicity. The Southwest Oncology Group (SWOG) conducted a phase II trial of piroxantrone in advanced soft tissue sarcoma. Treatment consisted of piroxantrone 150 mg/M2 administered intravenously over 1 hour every 21 days. Twenty-five eligible patients were registered to the trial. Twenty-three patients received treatment and are fully evaluable for response and toxicity. Two partial responses were seen for an overall response rate of 9% (95% confidence limit 1%–28%). Abnormal cardiac ejection fraction occurred in five patients, and fatal congestive heart failure developed in one patient on study. Toxicities other than cardiac were tolerable. Based on the observed response rate and cardiac toxicity, further trials of piroxantrone in the treatment of soft tissue sarcoma do not appear warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chang AE, Rosenberg SA, Glatstein EJ, Antman KH: Sarcomas of soft tissues. In: Cancer Principals and Practice of Oncology. 3rd Edition. J.B. Lippincott, Philadelphia PA, 1989, pp 1345–1398

  2. Von Hoff DD, Layard MW, Basa P, Davis Jr. HL, Von Hoff AL, Rozencweig M, Young RC, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717, 1979

    PubMed  Google Scholar 

  3. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43:460–472, 1983

    PubMed  Google Scholar 

  4. Showalter HDH, Johnson JL, Werbel LM, Leopold WR, Jackson RC, Elslager EF: 5-[(Aminoalkyl)amino]-substituted anthral [1,9-crf]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. J Med Chem 27:253–255, 1984

    PubMed  Google Scholar 

  5. Hacker MP, Newman RA, Fagan MS: The fetal mouse heart: a potential model for anthracycline-induced cardiotoxicity. Drugs Exp Clin Res 9:39–44, 1983

    Google Scholar 

  6. Fry DW, Boritzki TJ, Besserer JA, Jackson RC:In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-crf]pryazol-6(2H)-ones (anthrapyrazoles). Biochem Pharmacol 34:3499–3508, 1985

    Article  PubMed  Google Scholar 

  7. Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, Noe DA, Grochow LB: Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res 50:3284–3288, 1990

    Google Scholar 

  8. Ames MM, Loprinzi CL, Collins JM, van Haelst-Pisani C, Richardson RL, Rubin J, Moertel CG: Phase I and clinical pharmacological evaluation of piroxantrone hydrochloride (Oxantrazole). Cancer Res 50:3905–3909, 1990

    Google Scholar 

  9. Miller A, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981

    PubMed  Google Scholar 

  10. Clarke BV, Harwood KV, Donehower R: Local toxicity of piroxantrone: an anthrapyrazole with irritant and vesicant properties similar to doxorubicin (letter). J Natl Cancer Instit. 81:1331–1332, 1989

    Google Scholar 

  11. Allen A, Wolf M, Crawford ED, Davis MP, Natale RB, Barnett ML: Phase II evaluation of piroxantrone in renal cell carcinoma: A Southwest Oncology Group Study. Inv N Drugs 10:129–132, 1992

    Google Scholar 

  12. Williamson SK, Crowley JJ, Livingston R, Hantel A, Doroshow JH: Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group Study. Inv N Drugs 10:29–30, 1992

    Google Scholar 

  13. Savarese D, Berg S, Denicoff A, Hillig M, O'Shaughnessy J, Otterson G, Balis F, Poplack D, Cowan K. Phase I/pharmacokinetic study of piroxantrone and granulocyte colonystimulating factor (G-CSF) (Meeting abstract) Proc. AACR 33:1459, 1992

    Google Scholar 

  14. Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, Bonnet JD, Weiss GR, Ryan J, Benjamin RS, Baker LH: Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: A Southwest Oncology Group Study. J Natl Cancer Inst. 83:926–932, 1991

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wayne State University Medical Center, Detroit, MI

    Mark M. Zalupski

  2. Southwest Oncology Group Statistical Center, Seattle, WA

    Jacqueline Benedetti

  3. Ohio State University Health Center, Columbus, OH

    Stanley P. Balcerzak

  4. University of Arkansas for Medical Science, Little Rock, AR

    Laura F. Hutchins

  5. Kansas City Clinical Oncology Program, Kansas City, MO

    Robert J. Belt

  6. Loyola University Stritch School of Medicine, Maywood, IL

    Alexander Hantel

  7. Ozarks, CCOP, Springfield, MO, USA

    John Wendall Goodwin

Authors
  1. Mark M. Zalupski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacqueline Benedetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stanley P. Balcerzak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laura F. Hutchins
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert J. Belt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alexander Hantel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. John Wendall Goodwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zalupski, M.M., Benedetti, J., Balcerzak, S.P. et al. Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. Invest New Drugs 11, 337–341 (1993). https://doi.org/10.1007/BF00874435

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00874435

Key words

Search

Navigation